GlassScriptPhysician profile
Michael H Davidian
NPI 1780780163
$9,139.90
in general payments reported to CMS, 2019-2025
42 companies · $32.56 in 2025
The $32.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,964 · 2020: $469 · 2021: $973 · 2022: $1,758 · 2023: $1,995 · 2024: $950 · 2025: $32.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,253.86 | 2019-2024 | Airsupra, Farxiga, Bevespi Aerosphere |
| Lilly USA, LLC | $874.52 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $798.67 | 2019-2023 | |
| Amgen INC. | $733.44 | 2019-2024 | Prolia, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $442.76 | 2021-2024 | |
| Novo Nordisk INC | $399.94 | 2019-2023 | Rybelsus, Ozempic |
| Abbott Laboratories | $368.95 | 2019-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $315.54 | 2019-2024 | |
| Amarin Pharma, INC. | $271.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.82 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Ascensia Diabetes Care US INC. | $215.21 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $199.69 | 2019-2021 | |
| Astellas Pharma US INC | $198.66 | 2023-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $195.58 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $194.31 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davidian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.